CY1106607T1 - 4-(2-βουτυλαμιονο)-2,7-διμεθυλ-8-(2-μεθυλ-6-μεθοξυπυριδ-3-υλ) πυραζολο-1,5-αι-1,3,5-τριαζινη, τα εναντιομορα και φαρμακευτικως παραδεκτα αλατα αυτης ως συναρμοτες του υποδοχεα του παραγοντος απελευθερωσης κορτικοτροπινης - Google Patents
4-(2-βουτυλαμιονο)-2,7-διμεθυλ-8-(2-μεθυλ-6-μεθοξυπυριδ-3-υλ) πυραζολο-1,5-αι-1,3,5-τριαζινη, τα εναντιομορα και φαρμακευτικως παραδεκτα αλατα αυτης ως συναρμοτες του υποδοχεα του παραγοντος απελευθερωσης κορτικοτροπινηςInfo
- Publication number
- CY1106607T1 CY1106607T1 CY20071100678T CY071100678T CY1106607T1 CY 1106607 T1 CY1106607 T1 CY 1106607T1 CY 20071100678 T CY20071100678 T CY 20071100678T CY 071100678 T CY071100678 T CY 071100678T CY 1106607 T1 CY1106607 T1 CY 1106607T1
- Authority
- CY
- Cyprus
- Prior art keywords
- corticotropin
- enantimores
- butylamione
- methoxypyrid
- pyrazole
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Psychology (AREA)
Abstract
Ανταγωνιστές του παράγοντος απελευθέρωσης κορτικοτροπίνης (CRF) του τύπου (I) και η χρήση των στην θεραπευτική αγωγή από άγχος και κατάθλιψη και άλλες ψυχιατρικές, νευρολογικές διαταραχές καθώς και στην θεραπευτική αγωγή ανοσολογικών, καρδιαγγειακών ή σχετικών με την καρδιά ασθενειών και υπερευαισθησίας κόλου σε συνδυασμό με ψυχοπαθολογική διατάραξη και στρες.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27540301P | 2001-03-13 | 2001-03-13 | |
| PCT/US2002/006837 WO2002072202A1 (en) | 2001-03-13 | 2002-03-06 | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106607T1 true CY1106607T1 (el) | 2012-01-25 |
Family
ID=23052141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100678T CY1106607T1 (el) | 2001-03-13 | 2007-05-18 | 4-(2-βουτυλαμιονο)-2,7-διμεθυλ-8-(2-μεθυλ-6-μεθοξυπυριδ-3-υλ) πυραζολο-1,5-αι-1,3,5-τριαζινη, τα εναντιομορα και φαρμακευτικως παραδεκτα αλατα αυτης ως συναρμοτες του υποδοχεα του παραγοντος απελευθερωσης κορτικοτροπινης |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US20030125330A1 (el) |
| EP (1) | EP1368094B1 (el) |
| JP (1) | JP4549630B2 (el) |
| KR (1) | KR100875595B1 (el) |
| CN (1) | CN100427093C (el) |
| AR (1) | AR032986A1 (el) |
| AT (1) | ATE355102T1 (el) |
| AU (1) | AU2002245605B2 (el) |
| BG (1) | BG66331B1 (el) |
| BR (1) | BR0208357A (el) |
| CA (1) | CA2440553C (el) |
| CY (1) | CY1106607T1 (el) |
| CZ (1) | CZ20032481A3 (el) |
| DE (1) | DE60218434T2 (el) |
| DK (1) | DK1368094T3 (el) |
| EE (1) | EE05433B1 (el) |
| ES (1) | ES2282401T3 (el) |
| GE (1) | GEP20053608B (el) |
| HK (1) | HK1057182A1 (el) |
| HR (1) | HRP20030822B1 (el) |
| HU (1) | HU229317B1 (el) |
| IL (2) | IL157615A0 (el) |
| IS (1) | IS2839B (el) |
| MX (1) | MXPA03008185A (el) |
| MY (1) | MY146935A (el) |
| NO (1) | NO328580B1 (el) |
| NZ (1) | NZ528207A (el) |
| PL (1) | PL208278B1 (el) |
| PT (1) | PT1368094E (el) |
| RS (1) | RS50863B (el) |
| RU (1) | RU2292347C2 (el) |
| SK (1) | SK287603B6 (el) |
| TW (1) | TWI257388B (el) |
| UA (1) | UA74634C2 (el) |
| WO (1) | WO2002072202A1 (el) |
| ZA (1) | ZA200306995B (el) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094782B1 (en) * | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| CZ20032481A3 (cs) * | 2001-03-13 | 2007-12-27 | Bristol-Myers Squibb Pharma Company | 4-(2-Butylamino)-2, 7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo[1,5-A]-1, 3, 5-triazin, jeho enantiomery a farmaceuticky prijatelné soli jakoligandy receptoru faktoru uvolnujícího kortikotropin |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| AR041470A1 (es) | 2002-10-17 | 2005-05-18 | Upjohn Co | Compuestos de pirrolo (1,2 - b) piridazina y sus usos |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7041671B2 (en) * | 2003-04-02 | 2006-05-09 | Pfizer Inc | Pyrrolo[1,2-b]pyridazine compounds and their uses |
| US7056920B2 (en) | 2003-04-04 | 2006-06-06 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| US7034023B2 (en) | 2003-04-04 | 2006-04-25 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| BRPI0409444A (pt) * | 2003-04-15 | 2006-04-18 | Pharmacia & Upjohn Co Llc | compostos de pirrolo[1,2-b]piridazina e suas utilizações |
| US7208596B2 (en) * | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
| US7153961B2 (en) * | 2003-11-25 | 2006-12-26 | Bristol-Myers Squibb Pharma Co. | Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist |
| WO2008036579A1 (en) * | 2006-09-20 | 2008-03-27 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| WO2013160317A2 (en) * | 2012-04-23 | 2013-10-31 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| KR102079844B1 (ko) * | 2016-09-20 | 2020-02-20 | 가톨릭대학교 산학협력단 | 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물 |
| IL300478A (en) | 2020-08-12 | 2023-04-01 | Spruce Biosciences Inc | Methods and preparations for the treatment of polycystic ovary syndrome |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| EP0901476A4 (en) | 1996-03-26 | 2001-08-16 | Du Pont Pharm Co | PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| AU3064397A (en) | 1996-05-24 | 1997-12-09 | Dow Chemical Company, The | Process for preparing aliphatic ester compounds and alkanols |
| NZ333777A (en) * | 1996-07-24 | 2000-07-28 | Du Pont Pharm Co | (1,5-a) pyrazolo and triazole triazines and pyrimidines |
| KR100548853B1 (ko) | 1996-07-24 | 2006-02-02 | 브리스톨-마이어스 스퀴브 파마 컴파니 | 아졸로 트리아진 및 피리미딘 |
| US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| CA2263566C (en) * | 1996-08-28 | 2003-09-09 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
| AU8181098A (en) | 1997-07-03 | 1999-01-25 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| UA62972C2 (en) | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
| HUP0100179A3 (en) | 1997-07-03 | 2002-12-28 | Bristol Myers Squibb Pharma Co | Imidazopyrimidine and imidazopyridine derivatives and pharmaceutical compositions thereof |
| WO1999011643A1 (en) | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| SI1344779T1 (sl) * | 1998-01-28 | 2006-02-28 | Bristol Myers Squibb Pharma Co | Azolo-pirimidini |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| AU3213699A (en) | 1998-04-03 | 1999-10-25 | Du Pont Pharmaceuticals Company | Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists |
| US6124463A (en) | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
| CZ20032481A3 (cs) * | 2001-03-13 | 2007-12-27 | Bristol-Myers Squibb Pharma Company | 4-(2-Butylamino)-2, 7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo[1,5-A]-1, 3, 5-triazin, jeho enantiomery a farmaceuticky prijatelné soli jakoligandy receptoru faktoru uvolnujícího kortikotropin |
-
2002
- 2002-03-06 CZ CZ20032481A patent/CZ20032481A3/cs unknown
- 2002-03-06 MX MXPA03008185A patent/MXPA03008185A/es active IP Right Grant
- 2002-03-06 RU RU2003130093/04A patent/RU2292347C2/ru not_active IP Right Cessation
- 2002-03-06 DK DK02713776T patent/DK1368094T3/da active
- 2002-03-06 PL PL368644A patent/PL208278B1/pl unknown
- 2002-03-06 HU HU0303480A patent/HU229317B1/hu not_active IP Right Cessation
- 2002-03-06 RS YUP-715/03A patent/RS50863B/sr unknown
- 2002-03-06 ES ES02713776T patent/ES2282401T3/es not_active Expired - Lifetime
- 2002-03-06 WO PCT/US2002/006837 patent/WO2002072202A1/en active IP Right Grant
- 2002-03-06 NZ NZ528207A patent/NZ528207A/en not_active IP Right Cessation
- 2002-03-06 SK SK1157-2003A patent/SK287603B6/sk not_active IP Right Cessation
- 2002-03-06 PT PT02713776T patent/PT1368094E/pt unknown
- 2002-03-06 CN CNB028064151A patent/CN100427093C/zh not_active Expired - Fee Related
- 2002-03-06 EP EP02713776A patent/EP1368094B1/en not_active Expired - Lifetime
- 2002-03-06 IL IL15761502A patent/IL157615A0/xx unknown
- 2002-03-06 AU AU2002245605A patent/AU2002245605B2/en not_active Ceased
- 2002-03-06 JP JP2002571157A patent/JP4549630B2/ja not_active Expired - Fee Related
- 2002-03-06 EE EEP200300435A patent/EE05433B1/xx not_active IP Right Cessation
- 2002-03-06 BR BR0208357-4A patent/BR0208357A/pt active Search and Examination
- 2002-03-06 DE DE60218434T patent/DE60218434T2/de not_active Expired - Lifetime
- 2002-03-06 KR KR1020037011913A patent/KR100875595B1/ko not_active IP Right Cessation
- 2002-03-06 GE GE5322A patent/GEP20053608B/en unknown
- 2002-03-06 CA CA2440553A patent/CA2440553C/en not_active Expired - Fee Related
- 2002-03-06 AT AT02713776T patent/ATE355102T1/de active
- 2002-03-06 US US10/092,312 patent/US20030125330A1/en not_active Abandoned
- 2002-03-12 MY MYPI20020879A patent/MY146935A/en unknown
- 2002-03-13 AR ARP020100908A patent/AR032986A1/es not_active Application Discontinuation
- 2002-03-13 TW TW091104706A patent/TWI257388B/zh not_active IP Right Cessation
- 2002-06-03 UA UA2003109244A patent/UA74634C2/uk unknown
-
2003
- 2003-02-05 US US10/358,652 patent/US7157578B2/en not_active Expired - Lifetime
- 2003-08-27 IL IL157615A patent/IL157615A/en not_active IP Right Cessation
- 2003-09-08 ZA ZA200306995A patent/ZA200306995B/en unknown
- 2003-09-10 IS IS6947A patent/IS2839B/is unknown
- 2003-09-11 NO NO20034023A patent/NO328580B1/no not_active IP Right Cessation
- 2003-09-23 BG BG108189A patent/BG66331B1/bg unknown
- 2003-10-10 HR HR20030822A patent/HRP20030822B1/xx not_active IP Right Cessation
-
2004
- 2004-01-02 HK HK04100028A patent/HK1057182A1/xx not_active IP Right Cessation
-
2006
- 2006-11-07 US US11/593,715 patent/US7358252B2/en not_active Expired - Lifetime
-
2007
- 2007-05-18 CY CY20071100678T patent/CY1106607T1/el unknown
-
2008
- 2008-02-13 US US12/030,439 patent/US7662817B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106607T1 (el) | 4-(2-βουτυλαμιονο)-2,7-διμεθυλ-8-(2-μεθυλ-6-μεθοξυπυριδ-3-υλ) πυραζολο-1,5-αι-1,3,5-τριαζινη, τα εναντιομορα και φαρμακευτικως παραδεκτα αλατα αυτης ως συναρμοτες του υποδοχεα του παραγοντος απελευθερωσης κορτικοτροπινης | |
| DK1049699T3 (da) | Pyrazolotriaziner som CRF-antagonister | |
| LV12292A (lv) | Triazinu un pirimidinu azoloatvasinajumi | |
| ATE447561T1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
| NO952398L (no) | Pyrrolpyrimidiner som CRF antagonister | |
| PT1054887E (pt) | Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y | |
| BR0209575A (pt) | Pirazinonas, piridinas e pirimidinas substituìdas como ligantes do fator liberador de corticotropina | |
| DK0901374T3 (da) | Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser | |
| BR9307664A (pt) | Pirazóis substituídos como antagonistas | |
| MY130489A (en) | Substituted aryl 1, 4-pyrazine derivatives | |
| ATE384972T1 (de) | Progressive additionslinsen mit regressiven oberflächen | |
| CY1106816T1 (el) | 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση | |
| CY1105979T1 (el) | Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων | |
| EA200400399A1 (ru) | Способы лечения легочных заболеваний | |
| CY1105541T1 (el) | Παμοϊκα αλατα πιπεριδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων | |
| DE60204882D1 (de) | Zykloalkenylsulfonamidderivate | |
| MY141976A (en) | Azolo triazines and pyrimidines | |
| MY141752A (en) | Pyrazolotriazines as crf antagonists | |
| MY141511A (en) | Azolo triazines and pyrimidines |